Colombia Gastric Cancer Drugs Market Analysis

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF COLOMBIA GASTRIC CANCER DRUGS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.7 MULTIVARIATE MODELLING

2.8 TYPE LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET END USER COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTERS FIVE FORCES

5 COLOMBIA GASTRIC CANCER DRUGS MARKET: REGULATORY SCENARIO

6 SUMMARY WRITE UP (COLOMBIA)

6.1 OVERVIEW

7 PIPELINE ANALYSIS FOR COLOMBIA GASTRIC CANCER DRUGS MARKET

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 GROWING GASTRIC CANCER BURDEN WORLDWIDE

8.1.2 GROWING GERIATRIC POPULATION

8.1.3 INCREASING INITIATIVES BY GOVERNMENT AND OTHER HEALTHCARE ORGANISATIONS

8.1.4 RISING NUMBER OF PRODUCT APPROVALS

8.2 RESTRAINTS

8.2.1 ADVERSE EFFECTS AND RISKS ASSOCIATED WITH GASTRIC CANCER TREATMENT DRUGS

8.2.2 LACK OF EARLY DETECTION OF GASTRIC CANCER

8.3 OPPORTUNITIES

8.3.1 RECENT ADVANCEMENTS IN GASTRIC CANCER TREATMENT

8.3.2 ADOPTION OF AUTOMATED SYSTEMS

8.3.3 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS

8.4 CHALLENGES

8.4.1 CHALLENGE RELATED TO COLOMBIAN HEALTHCARE

8.4.2 ALTERNATIVE GASTRIC CANCER THERAPIES

9 IMPACT OF COVID-19 PANDEMIC ON COLOMBIA GASTRIC CANCER DRUGS MARKET

9.1 PRICE IMPACT

9.2 IMPACT ON DEMAND

9.3 IMPACT ON SUPPLY CHAIN

9.4 STRATEGIC DECISIONS FOR MANUFACTURERS

9.5 CONCLUSION

10 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY TYPE

10.1 OVERVIEW

10.2 ADENOCARCINOMA

10.3 GASTROINTESTINAL STROMAL TUMOR

10.4 CARCINOID TUMOR

10.5 LYMPHOMA

10.6 OTHERS

11 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY STAGES

11.1 OVERVIEW

11.2 STAGE III

11.3 STAGE II

11.4 STAGE IV

11.5 STAGE I

11.6 OTHERS

12 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY TREATMENT

12.1 OVERVIEW

12.2 CHEMOTHERAPY

12.2.1 CISPLATIN

12.2.2 OXALIPLATIN

12.2.3 FLUOROURACIL

12.2.4 DOCETAXEL

12.2.5 CAPECITABINE

12.2.6 CARBOPLATIN

12.2.7 EPIRUBICIN

12.2.8 PACLITAXEL

12.2.9 IRINOTECAN

12.2.10 OTHERS

12.3 TARGETED THERAPY

12.3.1 MONOCLONAL ANTIBODY THERAPY

12.3.1.1 TRASTUZUMAB (HERCEPTIN)

12.3.1.2 RAMUCIRUMAB

12.3.2 MULTIKINASE INHIBITORS

12.3.2.1 SUNITINIB

12.3.2.2 REGORAFENIB

12.4 IMMUNE CHECKPOINT INHIBITORS

12.5 OTHERS

13 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION

13.1 OVERVIEW

13.2 PARENTERAL

13.2.1 INTRAVENOUS

13.2.2 SUBCUTANEOUS

13.2.3 OTHERS

13.3 ORAL

13.3.1 TABLET

13.3.2 CAPSULE

13.3.3 OTHERS

13.4 OTHERS

13.5 OVERVIEW

13.6 HOSPITALS

13.7 SPECIALITY CLINICS

13.8 RESEARCH & ACADEMIC INSTITUTES

13.9 OTHERS

14 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 HOSPITAL PHARMACY

14.3 RETAIL PHARMACY

14.4 OTHERS

15 COLOMBIA GASTRIC CANCER DRUGS MARKET: COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: GLOBAL

16 SWOT ANALYSIS

17 COMPANY PROFILE

17.1 F.HOFFMAN-LA ROCHE

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 PRODUCT PORTFOLIO

17.1.4 RECENT DEVELOPMENT

17.1.4.1 AGREEMENT

17.2 MERCK KGAA (A SUBSIDIARY OF MERCK & CO., INC.)

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 PRODUCT PORTFOLIO

17.2.4 RECENT DEVELOPMENTS

17.2.4.1 PRODUCT APPROVAL

17.2.4.2 EVENTS

17.3 TEVA PHARMACEUTICAL INDUSTRIES LTD

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 PRODUCT PORTFOLIO

17.3.4 RECENT DEVELOPMENT

17.3.4.1 COLLABORATION

17.4 SANOFI

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 PRODUCT PORTFOLIO

17.4.4 RECENT DEVELOPMENT

17.4.4.1 ACQUISITION

17.5 ASTRAZENECA

17.5.1 COMPANY SNAPSHOT

17.5.2 REVENUE ANALYSIS

17.5.3 PRODUCT PORTFOLIO

17.5.4 RECENT DEVELOPMENT

17.5.4.1 PRODUCT APPROVAL

17.6 BAYER AG

17.6.1 COMPANY SNAPSHOT

17.6.2 REVENUE ANALYSIS

17.6.3 PRODUCT PORTFOLIO

17.6.4 RECENT DEVELOPMENT

17.6.4.1 COLLABORATION

17.7 BRISTOL-MYERS SQUIBB COMPANY

17.7.1 COMPANY SNAPSHOT

17.7.2 REVENUE ANALYSIS

17.7.3 PRODUCT PORTFOLIO

17.7.4 RECENT DEVELOPMENT

17.7.4.1 PRODUCT APPROVAL

17.8 CELLTRION HEALTHCARE CO., LTD.

17.8.1 COMPANY SNAPSHOT

17.8.2 REVENUE ANALYSIS

17.8.3 PRODUCT PORTFOLIO

17.8.4 RECENT DEVELOPMENT

17.8.4.1 PRODUCT APPROVAL

17.9 CONCORD BIOTECH.

17.9.1 COMPANY SNAPSHOT

17.9.2 PRODUCT PORTFOLIO

17.9.3 RECENT DEVELOPMENT

17.1 GLAXOSMITHKLINE PLC.

17.10.1 COMPANY SNAPSHOT

17.10.2 REVENUE ANALYSIS

17.10.3 PRODUCT PORTFOLIO

17.10.4 RECENT DEVELOPMENT

17.10.4.1 PRODUCT APPROVAL

17.11 NOVARTIS AG

17.11.1 COMPANY SNAPSHOT

17.11.2 REVENUE ANALYSIS

17.11.3 PRODUCT PORTFOLIO

17.11.4 RECENT DEVELOPMENT

17.11.4.1 PRODUCT LAUNCH

17.12 PFIZER INC.

17.12.1 COMPANY SNAPSHOT

17.12.2 REVENUE ANALYSIS

17.12.3 PRODUCT PORTFOLIO

17.12.4 RECENT DEVELOPMENTS

17.12.4.1 MERGER

17.12.4.2 COLLABORATION

17.13 VIATRIS INC.

17.13.1 COMPANY SNAPSHOT

17.13.2 REVENUE ANALYSIS

17.13.3 PRODUCT PORTFOLIO

17.13.4 RECENT DEVELOPMENT

18 QUESTIONNAIRE

19 RELATED REPORTS